-
肝癌是临床最常见的恶性肿瘤之一,严重威胁人类的生命健康[1]。由于肝癌早期发病非常隐匿,患者就诊时多已经属于晚期,失去了手术的机会。截至目前,我国肝癌患者的5年生存率仍很低,仅为12.1%[2],患者的生存状况亟待改善。为提高肝癌患者的生活质量,研究者不断探索更为有效的治疗方法。对无手术适应症的中晚期肝癌患者,可选择肝动脉化疗栓塞术(transcranial arterial chemoembolization,TACE),但 TACE 治疗肝癌仍存在一定的局限性 [3]。新近提出的综合介入治疗概念是指在传统TACE的基础上,根据患者的病情,联合125I粒子植入治疗的一种综合治疗策略,并已逐渐成为肝癌非手术治疗的主要模式。本研究采用TACE技术联合放射性125I粒子植入治疗中晚期肝癌,并评价其临床疗效,以探讨中晚期肝癌有效的治疗方法和经验。
-
治疗组和对照组患者年龄的差异无统计学意义(χ2=0.574,P=0.283)。
-
由表1可知,治疗前治疗组患者的疼痛频率和疼痛程度与对照组的差异均无统计学意义(均P>0.05)。由表2可知,治疗后治疗组患者的疼痛频率较对照组患者降低,且差异有统计学意义(P<0.001);治疗组患者的疼痛程度较对照组患者缓解,且差异有统计学意义(P=0.037)。
组别 疼痛频率 疼痛程度(视觉模拟疼痛评分) ≤2 次/d ≥3 次/d 无痛 轻度 中度 重度 治疗组(125I粒子植入联合TACE治疗,n=69) 12(17.4) 57(82.6) 9(13.0) 16(23.2) 34(49.3) 10(14.5) 对照组(单独TACE治疗,n=54) 11(20.4) 43(79.6) 6(11.1) 11(20.4) 28(51.8) 9(16.7) χ2值 0.177 0.335 P值 0.674 0.953 注:TACE为肝动脉化疗栓塞术 表 1 125I粒子植入联合TACE治疗与单独TACE治疗中晚期肝癌患者治疗前疼痛缓解效果的比较 [ 例(%)]
Table 1. Comparison of pain assessment results of advanced liver cancer patients treated with 125I seed implantation combined with transcranial arterial chemoembolization and transcranial arterial chemoembolization alone before treatment (case (%))
-
由表3可知,治疗后3个月,治疗组治疗有效率为84.1%、疾病控制率为92.8%;对照组治疗有效率为22.2%、疾病控制率为51.9%,2组间的差异均有统计学意义(均P<0.001)。由表4可知,治疗6个月后,治疗组治疗有效率为62.3%、疾病控制率为79.7%;对照组治疗有效率为16.7%、疾病控制率为44.4%,2组间的差异均有统计学意义(均P<0.001)。
组别 疼痛频率 疼痛程度(视觉模拟疼痛评分) ≤2 次/d ≥3 次/d 无痛 轻度 中度 重度 治疗组(125I粒子植入联合TACE治疗,n=69) 65(94.2) 4(5.8) 21(30.4) 28(40.6) 17(24.6) 3(4.4) 对照组(单独TACE治疗,n=54) 38(70.4) 16(29.6) 12(22.2) 13(24.1) 22(40.7) 7(13.0) χ2值 123.00 8.480 P值 <0.001 0.037 注:TACE为肝动脉化疗栓塞术 表 2 125I粒子植入联合TACE治疗与单独TACE治疗的中晚期肝癌患者治疗后1个月疼痛缓解效果的比较 [ 例(%)]
Table 2. Comparison of pain assessment results of advanced liver cancer patients treated with 125I seed implantation combined with transcranial arterial chemoembolization and transcranial arterial chemoembolization alone after 1 month of treatment (case (%))
组别 完全缓解 部分缓解 稳定 进展 有效率 控制率 治疗组(125I粒子植入联合TACE治疗,n=69) 15(21.7) 43(62.3) 6(8.7) 5(7.2) 58(84.1)a 64(92.8)a 对照组(单独TACE治疗,n=54) 5(9.3) 7(13.0) 16(29.6) 26(48.1) 12(22.2) 28(51.9) 注:a表示与对照组比较,差异均有统计学意义(χ2=47.234、36.883,均P<0.001)。TACE为肝动脉化疗栓塞术 表 3 125I粒子植入联合TACE治疗与单独TACE治疗中晚期肝癌患者治疗后3个月疗效评估结果的比较 [ 例(%)]
Table 3. Comparison of the efficacy of advanced liver cancer patients treated with 125I seed implantation combined with transcranial arterial chemoembolization and transcranial arterial chemoembolization alone after 3 months of treatment (case (%))
组别 完全缓解 部分缓解 稳定 进展 有效率 控制率 治疗组(125I粒子植入联合TACE治疗,n=69) 8(11.6) 35(50.7) 12(17.4) 14(20.3) 43(62.3)a 55(79.7)a 对照组(单独TACE治疗,n=54) 3(5.6) 6(11.1) 15(27.8) 30(55.6) 9(16.7) 24(44.4) 注:a表示与对照组比较,差异均有统计学意义(χ2=25.871、17.999,均P<0.001)。TACE为肝动脉化疗栓塞术 表 4 125I粒子植入联合TACE治疗与单独TACE治疗的中晚期肝癌患者治疗后6个月疗效评估结果的比较 [ 例(%)]
Table 4. Comparison of the efficacy of advanced liver cancer patients treated with 125I seed implantation combined with transcranial arterial chemoembolization and transcranial arterial chemoembolization alone after 6 months of treatment (case (%))
治疗组患者的1年生存率为75.4%(52/69),高于对照组的33.3%(18/54),2组间的差异有统计学意义(χ2=21.821,P<0.001);治疗组患者的2年生存率为40.6%(28/69),高于对照组的13.0%(7/54),2组间的差异有统计学意义(χ2=11.349,P<0.001)。
放射性125I粒子植入联合肝动脉化疗栓塞术治疗中晚期肝癌的临床疗效评价
Efficacy evaluation of radioactive 125I seeds implantation combined with transcranial arterial chemoembolization in the treatment of advanced liver cancer
-
摘要:
目的 评价放射性125I粒子植入联合肝动脉化疗栓塞术(TACE)治疗中晚期肝癌的临床疗效。 方法 回顾性分析2014年1月至2019年12月于兰州市第一人民医院经穿刺活体组织病理学检查证实的123例中晚期肝癌患者的临床资料,其中男性73例、女性50例,年龄39~75(60.4±4.4)岁。以接受放射性125I粒子植入联合TACE治疗的患者为治疗组(69例),以接受单纯TACE治疗的患者为对照组(54例)。采用视觉模拟评分法(VAS)对所有患者进行疼痛评估,依据改良的实体瘤疗效评价标准(mRECIST)1.1版进行疗效评估。采用χ2检验进行2组间的比较。 结果 治疗后1个月治疗组疼痛频率≤2次/d的患者占94.2%(65/69)、≥3次/d的患者占5.8%(4/69),对照组疼痛频率≤2次/d的患者占70.4%(38/54)、≥3次/d的患者占29.6%(16/54),2组间的差异有统计学意义(χ2=123.00,P<0.001)。治疗后1个月治疗组无痛和轻度疼痛患者占71.0%(49/69)、中度疼痛占24.6%(17/69)、重度疼痛占4.4%(3/69),对照组无痛和轻度疼痛的患者占46.3%(25/54)、中度疼痛占40.7%(22/54)、重度疼痛占13.0%(7/54),2组间的差异有统计学意义(χ2=8.480,P<0.05)。治疗组患者治疗后3个月的治疗有效率和疾病控制率分别为84.1%(58/69)和92.8%(64/69),显著高于对照组的22.2%(12/54)和51.9%(28/54),2组间的差异均有统计意义(χ2=47.234、36.883,均P<0.001);治疗后6个月的治疗有效率和疾病控制率分别为62.3%(43/69)和79.7%(55/69),显著高于对照组的16.7%(9/54)和44.4%(24/54),2组间的差异均有统计意义(χ2=25.871、17.999,均P<0.001)。治疗组患者治疗后1年和2年的生存率分别为75.4%(52/69)和40.6%(28/69)、对照组分别为33.3%(18/54)和13.0%(7/54),2组间的差异均有统计学意义(χ2=21.821、11.349,均P<0.001)。 结论 放射性125I粒子植入联合TACE治疗对中晚期肝癌患者具有良好的治疗效果。 Abstract:Objectives To evaluate the clinical efficacy of radioactive 125I seed implantation combined with transcranial arterial chemoembolization (TACE) in the treatment of advanced liver cancer. Methods A total of 123 patients with advanced liver cancer by histopathology in the First People's Hospital of Lanzhou City, from January 2014 to December 2019 were retrospectively analyzed. The patients included 73 male patients and 50 female patients, aged 39−75(60.4±4.4) years old. Herein, patients who received radioactive 125I seed implantation combined with TACE were treated as the treatment group (69 cases), meanwhile, patients who received TACE alone were treated as the control group (54 cases). The visual analog scale (VAS) was used to evaluate the pain of all patients, and the efficacy was evaluated based on the modified Response Evaluation Criteria for Solid Tumors (mRECIST) version 1.1. χ2 test was used to compare the two groups. Results After 1 month of treatment, 94.2%(65/69) of patients in the treatment group had pain frequency of ≤2 times/d, and 5.8%(4/69) of patients with pain frequency of ≥3 times/d. Meanwhile, 70.4%(38/54) of patients in the control group had pain frequency of ≤2 times/d, and 29.6%(16/54) of patients with pain frequency of ≥3 times/d. Hence, the difference between the two groups was statistically significant (χ2=123.00, P<0.001). After 1 month of treatment, 71.0%(49/69) of patients in the treatment group had no pain or mild pain, 24.6%(17/69) had moderate pain, and 4.4%(3/69) had severe pain. Meanwhile, in the control group, 46.3%(25/54) of patients had no pain or mild pain, 40.7%(22/54) experienced moderate pain, and 13.0%(7/54) had severe pain. Thus, the difference between the two groups was statistically significant (χ2=8.480, P<0.05). After 3 months of treatment, the effective rate and disease control rate of the treatment group were 84.1%(58/69) and 92.8%(64/69), respectively, which were significantly higher than those of the control group (22.2%(12/54) and 51.9%(28/54)), and the differences were statistically significant (χ2=47.234, 36.883; P<0.001). After 6 months of treatment, the effective rate and disease control rate of the treatment group were 62.3%(43/69) and 79.7%(55/69), respectively, which were significantly higher than 16.7%(9/54) and 44.4%(24/54) of the control group, and the differences between the two groups were statistically significant (χ2=25.871, 17.999; both P<0.001). In addition, the 1- and 2-year survival rates were 75.4%(52/69) and 40.6%(28/69) in the treatment group and 33.3%(18/54) and 13.0%(7/54) in the control group, respectively, and the difference was statistically significant (χ2=21.821, 11.349; both P<0.001). Conclusion Radioactive 125I seed implantation combined with TACE treatment therapy has a good therapeutic effect on patients with advanced liver cancer. -
表 1 125I粒子植入联合TACE治疗与单独TACE治疗中晚期肝癌患者治疗前疼痛缓解效果的比较 [ 例(%)]
Table 1. Comparison of pain assessment results of advanced liver cancer patients treated with 125I seed implantation combined with transcranial arterial chemoembolization and transcranial arterial chemoembolization alone before treatment (case (%))
组别 疼痛频率 疼痛程度(视觉模拟疼痛评分) ≤2 次/d ≥3 次/d 无痛 轻度 中度 重度 治疗组(125I粒子植入联合TACE治疗,n=69) 12(17.4) 57(82.6) 9(13.0) 16(23.2) 34(49.3) 10(14.5) 对照组(单独TACE治疗,n=54) 11(20.4) 43(79.6) 6(11.1) 11(20.4) 28(51.8) 9(16.7) χ2值 0.177 0.335 P值 0.674 0.953 注:TACE为肝动脉化疗栓塞术 表 2 125I粒子植入联合TACE治疗与单独TACE治疗的中晚期肝癌患者治疗后1个月疼痛缓解效果的比较 [ 例(%)]
Table 2. Comparison of pain assessment results of advanced liver cancer patients treated with 125I seed implantation combined with transcranial arterial chemoembolization and transcranial arterial chemoembolization alone after 1 month of treatment (case (%))
组别 疼痛频率 疼痛程度(视觉模拟疼痛评分) ≤2 次/d ≥3 次/d 无痛 轻度 中度 重度 治疗组(125I粒子植入联合TACE治疗,n=69) 65(94.2) 4(5.8) 21(30.4) 28(40.6) 17(24.6) 3(4.4) 对照组(单独TACE治疗,n=54) 38(70.4) 16(29.6) 12(22.2) 13(24.1) 22(40.7) 7(13.0) χ2值 123.00 8.480 P值 <0.001 0.037 注:TACE为肝动脉化疗栓塞术 表 3 125I粒子植入联合TACE治疗与单独TACE治疗中晚期肝癌患者治疗后3个月疗效评估结果的比较 [ 例(%)]
Table 3. Comparison of the efficacy of advanced liver cancer patients treated with 125I seed implantation combined with transcranial arterial chemoembolization and transcranial arterial chemoembolization alone after 3 months of treatment (case (%))
组别 完全缓解 部分缓解 稳定 进展 有效率 控制率 治疗组(125I粒子植入联合TACE治疗,n=69) 15(21.7) 43(62.3) 6(8.7) 5(7.2) 58(84.1)a 64(92.8)a 对照组(单独TACE治疗,n=54) 5(9.3) 7(13.0) 16(29.6) 26(48.1) 12(22.2) 28(51.9) 注:a表示与对照组比较,差异均有统计学意义(χ2=47.234、36.883,均P<0.001)。TACE为肝动脉化疗栓塞术 表 4 125I粒子植入联合TACE治疗与单独TACE治疗的中晚期肝癌患者治疗后6个月疗效评估结果的比较 [ 例(%)]
Table 4. Comparison of the efficacy of advanced liver cancer patients treated with 125I seed implantation combined with transcranial arterial chemoembolization and transcranial arterial chemoembolization alone after 6 months of treatment (case (%))
组别 完全缓解 部分缓解 稳定 进展 有效率 控制率 治疗组(125I粒子植入联合TACE治疗,n=69) 8(11.6) 35(50.7) 12(17.4) 14(20.3) 43(62.3)a 55(79.7)a 对照组(单独TACE治疗,n=54) 3(5.6) 6(11.1) 15(27.8) 30(55.6) 9(16.7) 24(44.4) 注:a表示与对照组比较,差异均有统计学意义(χ2=25.871、17.999,均P<0.001)。TACE为肝动脉化疗栓塞术 -
[1] 杨帆, 曹毛毛, 李贺, 等. 1990—2019年中国人群肝癌流行病学趋势分析及预测[J]. 中华消化外科杂志, 2022, 21(1): 106−113. DOI: 10.3760/cma.j.cn115610-20211203-00616.
Yang F, Cao MM, Li H, et al. Analysis and prediction of the epidemiological trend of liver cancer in the Chinese population from 1990 to 2019[J]. Chin J Dig Surg, 2022, 21(1): 106−113. DOI: 10.3760/cma.j.cn115610-20211203-00616.[2] Zeng HM, Chen WQ, Zheng RS, et al. Changing cancer survival in China during 2003−15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5): e555−e567. DOI: 10.1016/s2214-109x(18)30127-x. [3] 毛利峰, 李可夫, 宁真真. CT引导下125I粒子植入术联合肝动脉栓塞化疗治疗40例晚期肝癌患者的临床研究[J]. 黑龙江医学, 2020, 44(7): 902−904. DOI: 10.3969/j.issn.1004-5775.2020.07.014.
Mao LF, Li KF, Ning ZZ. Clinical study of CT-guided 125I seed implantation combined with transcatheter arterial chemoembolization in the treatment of 40 patients with advanced liver cancer[J]. Heilongjiang Med J, 2020, 44(7): 902−904. DOI: 10.3969/j.issn.1004-5775.2020.07.014.[4] Ko KJ, Cho WJ, Lee YS, et al. Comparison of the efficacy between transurethral coagulation and transurethral resection of hunner lesion in interstitial cystitis/bladder pain syndrome patients: a prospective randomized controlled trial[J]. Eur Urology, 2020, 77(5): 644−651. DOI: 10.1016/j.eururo.2020.01.002. [5] Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010, 30(1): 52−60. DOI: 10.1055/s-0030-1247132. [6] 骆栋梁, 张维春, 吴迪, 等. 肝癌CT表现与癌组织病理分化程度及临床预后的相关性[J]. 中国CT和MRI杂志, 2019, 17(10): 65−68. DOI: 10.3969/j.issn.1672-5131.2019.10.022.
Luo DL, Zhang WC, Wu D, et al. Correlation of CT findings with pathological differentiation and clinical prognosis of hepatocellular carcinoma[J]. Chin J CT MRI, 2019, 17(10): 65−68. DOI: 10.3969/j.issn.1672-5131.2019.10.022.[7] 廖方, 邱金伦, 段进东, 等. MDT诊疗模式在肝癌患者治疗中的效果观察[J]. 包头医学院学报, 2021, 37(3): 86−89, 103. DOI: 10.16833/j.cnki.jbmc.2021.03.023.
Liao F, Qiu JL, Duan JD, et al. Observation on the effect of MDT collaborative diagnosis and treatment model in the treatment of patients with liver cancer[J]. J Baotou Med College, 2021, 37(3): 86−89, 103. DOI: 10.16833/j.cnki.jbmc.2021.03.023.[8] Lencioni R, de Baere T, Burrel M, et al. Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations[J]. Cardiovase Intervent Radiol, 2012, 35(5): 980−985. DOI: 10.1007/s00270-011-0287-7. [9] Lin ZY, Chen J, Deng XF, et al. Treatment of hepatocellular carcinoma adjacent to large blood vessels using 1.5T MRI-guided percutaneous radiofrequency ablation combined with iodine-125 radioactive seed implantation[J]. Eur J Radiol, 2012, 81(11): 3079−3083. DOI: 10.1016/j.ejrad.2012.05.007. [10] 叶世富, 首峰, 张景俊, 等. 放射粒子联合TACE介入治疗原发性肝癌的疗效以及对可溶性B7-H4的影响[J]. 实用癌症杂志, 2016, 31(9): 1402−1405. DOI: 10.3969/j.issn.1001-5930.2016.09.004.
Ye SF, Shou F, Zhang JJ, et al. Curative effect of radion combined with TACE intervention for primary liver cancer and its influence on soluble B7-H4[J]. Pract J Cancer, 2016, 31(9): 1402−1405. DOI: 10.3969/j.issn.1001-5930.2016.09.004.[11] 黄金铭, 于宁文. 125I放射性粒子治疗癌症研究进展[J]. 同位素, 2020, 33(3): 186−198. DOI: 10.7538/tws.2019.youxian.009.
Huang JM, Yu NW. Progress of permanent seed implantation using 125I seeds for cancer therapy[J]. Isotopes, 2020, 33(3): 186−198. DOI: 10.7538/tws.2019.youxian.009.[12] 陈晨, 陈金喜. 肝动脉导管化疗栓塞术联合125I放射粒子植入治疗原发性肝癌的效果[J]. 河南医学研究, 2018, 27(18): 3331−3333. DOI: 10.3969/j.Issn.1004-437X.2018.18.029.
Chen C, Chen JX. Effect of hepatic arteriocatheter chemoembolization combined with 125I radiation implantation in the treatment of primary liver cancer[J]. Henan Med Res, 2018, 27(18): 3331−3333. DOI: 10.3969/j.Issn.1004-437X.2018.18.029.[13] 李庆, 曹苏娟, 龙文兴, 等. 125I粒子植入术联合TACE 治疗大肝癌的临床效果[J]. 中国医药导报, 2016, 13(2): 73−77.
Li Q, Cao SJ, Long WX, et al. Clinical effect of 125I combined with TACE in the treatment of large hepatocellular carcinoma[J]. Chin Med Rep, 2016, 13(2): 73−77.[14] 朱超, 刘会春, 胡小四, 等. TACE联合125I粒子植入治疗原发性肝癌合并肝外转移的疗效分析[J]. 检验医学与临床, 2020, 17(14): 1969−1971. DOI: 10.3969/j.Issn.1672-9455.2020.14.007.
Zhu C, Liu HC, Hu XS, et al. Curative effect analysis of TACE combined with 125I seed implantation for hepatocellular carcinoma with extrahepatic metastasis[J]. Lab Med Clin, 2020, 17(14): 1969−1971. DOI: 10.3969/j.Issn.1672-9455.2020.14.007.[15] 任文君, 王泽阳, 黄欣, 等. 肝动脉化疗栓塞术联合125I 放射性粒子植入术与单独肝动脉化疗栓塞术治疗肝癌的meta分析[J]. 介入放射学杂志, 2019, 28(2): 132−137. DOI: 10.3969/j.Issn.1008-794X.2019.02.007.
Ren WJ, Wang ZY, Huang X, et al. TACE combined with 125I seed implantation vs simple TACE for the treatment of liver cancer: a meta analysis[J]. J Intervent Radiol, 2019, 28(2): 132−137. DOI: 10.3969/j.Issn.1008-794X.2019.02.007.[16] Ahmedzai SH, Bautista MJ, Bouzid K, et al. Optimizing cancer pain management in resource-limited settings[J]. Support Care Cancer, 2019, 27(6): 2113−2124. DOI: 10.1007/s00520-018-4471-z. [17] 梁百武, 何闯, 梁清华, 等. 腹膜后转移瘤放射性125I粒子植入治疗的靶区剂量研究[J]. 局解手术学杂志, 2021, 30(1): 58−61. DOI: 10.11659/jjssx.07E020121.
Liang BW, He C, Liang QH, et al. Dosimetric study on target area of radioactive 125I seeds implantation brachytherapy for retroperitoneal metastasis[J]. J Reg Anat Oper Sur, 2021, 30(1): 58−61. DOI: 10.11659/jjssx.07E020121.[18] 田永巍, 蒋强, 李宁, 等. 125I 粒子植入联合 TACE 治疗原发性肝癌的效果及对患者 IL-8和 IFN-γ水平的影响[J]. 实用癌症杂志, 2022, 37(3): 451−454. DOI: 10.3969/j.issn.1001-5930.2022.03.027.
Tian YW, Jiang Q, Li N, et al. The efficacy of 125I seed implantation combined with TACE in the treatment of primary liver cancer and its effect on the levels of IL-8 and IFN- γ in patients[J]. Pract J Cancer, 2022, 37(3): 451−454. DOI: 10.3969/j.issn.1001-5930.2022.03.027.